Funding for this research was provided by:
Idorsia Pharmaceuticals Ltd (Idorsia Pharmaceuticals Ltd)
Received: 8 June 2022
Accepted: 2 December 2022
First Online: 20 December 2022
: The study is conducted in full compliance with the International Conference on Harmonization Good Clinical Practice Guideline, the principles of the Declaration of Helsinki, and the laws and regulations of the country in which it is performed. The REACT protocol and amendments have been approved by research ethics committees/institutional review boards in each participating investigational site (last amendment dated February 18, 2022, Additional file InternalRef removed). It is the responsibility of the investigator to obtain written informed consent from all participants prior to enrolment in the study.
: Not applicable.
: NB, RH, EFA, and SAM have been consultants / scientific advisors for Idorsia Pharmaceuticals Ltd. and have received consulting fees.HSJ, AM, and SR are employees of Idorsia Pharmaceuticals Ltd., and CD is an external contractor. Idorsia is the owner and developer of clazosentan.